Paediatric oncologist Navin Pinto, MD outlines the current use and potential of CAR-T therapies in his field, including the manufacturing challenges that still need to be addressed. Dr Pinto also explains how the work of his CAR-T team at the University of Washington School of Medicine could provide proof of principle for pharma to take forward and make available more widely or expand to different indications.
A lot of work is going on to increase funding for paediatric cancer and many centres – mine included – are not necessarily waiting around for federal funding to come in but instead harnessing both cooperative agreements with pharmaceutical companies and the power of community resources and philanthropy to evaluate new therapies
